Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06835375 for adult primary immune thrombocytopenia
2023-509338-21-00Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2022
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, open-label trial of PF-06835375 in immune thrombocytopenia (ITP) (4 cohorts), sponsored by Pfizer. Primary endpoint: Log2 platelet count. Started Jan 2022; status: completed.
02
Drugs
PF-06835375
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2023-509338-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509338-21-00.